MannKind (MNKD) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
20 May, 2026Opening remarks and agenda
Meeting called to order with introductions of board members and corporate officers present, including remote participation.
Notice of meeting mailed to all stockholders; Inspector of Elections appointed and sworn in.
Quorum established with 233,461,993 shares represented, authorizing business transactions.
Board and executive committee updates
Nine directors nominated and elected to serve until the next annual meeting.
Board and executive team introduced, with CEO remarks scheduled after formal business.
Shareholder proposals
Three proposals presented: election of directors, advisory approval of executive compensation, and ratification of Deloitte & Touche as auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MannKind
- Q2 2026 revenue up 43% to $109.4M, driven by FUROSCIX and Afrezza pediatric launch.MNKD
Q2 2026 - Nintedanib DPI showed strong safety and efficient lung delivery in IPF, supporting Phase 2 trials.MNKDStudy result
- FDA approved FUROSCIX ReadyFlow, enabling rapid at-home IV-equivalent diuretic therapy.MNKDFDA announcement
- Diversified growth, new launches, and pipeline advances set the stage for accelerated revenue and margin expansion.MNKDLeerink Global Healthcare Conference 2026
- Pediatric Afrezza approval and FUROSCIX auto-injector drive growth amid strong pipeline progress.MNKDJefferies Global Healthcare Conference 2026
- FDA approved Afrezza for children 6+, enabling the first inhaled mealtime insulin for pediatrics.MNKDFDA announcement
- Q1 2026 revenue up 15% to $90.2M, but higher expenses led to a $16.6M net loss.MNKDQ1 2026
- Q4 and FY 2025 revenues surged, driven by FUROSCIX and Afrezza, with major 2026 catalysts ahead.MNKDQ4 2025
- Q1 revenue up 18% to $78.4M, net income up 24%, driven by Tyvaso DPI and Afrezza growth.MNKDQ1 2025